Propanc Biopharma Announces 1-for-10 Reverse Stock Split

Propanc Biopharma, Inc. has announced a 1-for-10 reverse stock split of its common stock, approved by its Board of Directors, to comply with Nasdaq's $1.00 minimum bid price requirement. The reverse split will take effect on October 26, 2026, while the stock will continue to trade under the ticker symbol 'PPCB.' CEO James Nathanielsz indicated that this move is aimed at facilitating future growth initiatives and clearing the way for upcoming R&D milestones, including a Phase 1b study for the lead asset, PRP, planned for the first quarter of 2027.